Treatment of hepatitis C is rapidly changing. It began with IFN monotherapy; then the addition of ribavirin doubled the rate of response and pegylation of IFN further improved it. The development of direct-acting antivirals has brought up combinations of even three or more drugs with the aim of reaching the 100% response rate. However, the development of potent direct-acting antivirals with high barrier to resistance gives the possibility of reaching this aim with just two drugs. This review will focus on dual therapy moving on from the past to the near future.
Francesco Azzaroli, Marco Montagnani, Alberto Porro, Domenico Fiorillo, Giuseppe Mazzella (2014). The future of dual therapy for hepatitis C virus. FUTURE VIROLOGY, 9, 905-912 [10.2217/fvl.14.78].
The future of dual therapy for hepatitis C virus
Francesco AzzaroliConceptualization
;Marco MontagnaniSupervision
;Alberto PorroMembro del Collaboration Group
;Giuseppe Mazzella
Conceptualization
2014
Abstract
Treatment of hepatitis C is rapidly changing. It began with IFN monotherapy; then the addition of ribavirin doubled the rate of response and pegylation of IFN further improved it. The development of direct-acting antivirals has brought up combinations of even three or more drugs with the aim of reaching the 100% response rate. However, the development of potent direct-acting antivirals with high barrier to resistance gives the possibility of reaching this aim with just two drugs. This review will focus on dual therapy moving on from the past to the near future.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
